When a patient may have less weight to lose in general, or they are reluctant to be on longer-term medication, phentermine can be a good option, says Vukasinov
To keep the model practical, we focus on a short list of inputs that move the market the most, such as type 2 diabetes and obesity prevalence trends, share of eligible patients who initiate GLP-1 therapy, persistence and discontinuation behavior, the split between diabetes and weight management demand, and the net price direction after rebates and coverage decisions
This may include the desire for more darkly pigmented skin (via increased melanin production), greater muscle definition, a reduction in appetite, greater libido, more rapid recovery, greater confidence, better selfies, leading to greater engagement
Switching GLP-1s Stopping GLP-1s Wraparound support in weight loss Inappropriate access to GLP-1s What are GLP-1s
Meanwhile, many employers are dropping obesity drug coverage due to short-term cost concerns, despite the overwhelming evidence that effective treatment reduces downstream healthcare costs
